FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108134400> ?p ?o ?g. }

• W2108134400 abstract "Stereotactic body radiotherapy (SBRT) may yield disease control for prostate cancer in a brief, hypofractionated treatment regimen without increasing treatment toxicity. Our report presents a 6-year update from 304 low- (n = 211), intermediate- (n = 81), and high-risk (n = 12) prostate cancer patients who received CyberKnife SBRT. The median PSA at presentation was 5.8 ng/ml. Fifty-seven patients received neoadjuvant hormonal therapy for up to one year. The first 50 patients received a total dose of 35 Gy in 5 fractions of 7 Gy. The subsequent 254 patients received a total dose of 36.25 Gy in 5 fractions of 7.25 Gy. Toxicity was assessed with the Expanded Prostate Cancer Index Composite questionnaire and the Radiation Therapy Oncology Group urinary and rectal toxicity scale. Biochemical failure was assessed using the nadir + 2 definition. No patients experienced Grade III or IV acute complications. Fewer than 5% of patients experienced any acute Grade II urinary or rectal toxicities. Late urinary Grade II complications were observed in 4% of patients treated to 35 Gy and 9% of patients treated to 36.25 Gy. Five (2%) late Grade III urinary toxicities occurred in patients who were treated with 36.25 Gy. Late Grade II rectal complications were observed in 2% of patients treated to 35 Gy and 5% of patients treated to 36.25 Gy. Bowel and urinary quality of life (QOL) scores initially decreased, but later returned to baseline values. An overall decrease of 20% in the sexual QOL score was observed. QOL in each domain was not differentially affected by dose. For patients that were potent prior to treatment, 75% stated that they remained sexually potent. Actuarial 5-year biochemical recurrence-free survival was 97% for low-risk, 90.7% for intermediate-risk, and 74.1% for high-risk patients. PSA fell to a median of 0.12 ng/ml at 5 years; dose did not influence median PSA levels. In this large series with long-term follow-up, we found excellent biochemical control rates and low and acceptable toxicity, outcomes consistent with those reported for from high dose rate brachytherapy (HDR BT). Provided that measures are taken to account for prostate motion, SBRT’s distinct advantages over HDR BT include its noninvasiveness and delivery to patients without anesthesia or hospitalization." @default.
• W2108134400 created "2016-06-24" @default.
• W2108134400 creator A5013286247 @default.
• W2108134400 creator A5030399585 @default.
• W2108134400 creator A5038451619 @default.
• W2108134400 creator A5082915859 @default.
• W2108134400 date "2013-05-13" @default.
• W2108134400 modified "2023-09-27" @default.
• W2108134400 title "Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years" @default.
• W2108134400 cites W1516952155 @default.
• W2108134400 cites W1966768680 @default.
• W2108134400 cites W1979665150 @default.
• W2108134400 cites W1983228790 @default.
• W2108134400 cites W1987470170 @default.
• W2108134400 cites W2000238692 @default.
• W2108134400 cites W2002612178 @default.
• W2108134400 cites W2014228954 @default.
• W2108134400 cites W2020242089 @default.
• W2108134400 cites W2025691442 @default.
• W2108134400 cites W2027570282 @default.
• W2108134400 cites W2071750479 @default.
• W2108134400 cites W2080122759 @default.
• W2108134400 cites W2088223021 @default.
• W2108134400 cites W2093867637 @default.
• W2108134400 cites W2096260602 @default.
• W2108134400 cites W2096568394 @default.
• W2108134400 cites W2101001966 @default.
• W2108134400 cites W2104631398 @default.
• W2108134400 cites W2115675646 @default.
• W2108134400 cites W2117728681 @default.
• W2108134400 cites W2120455310 @default.
• W2108134400 cites W2124537997 @default.
• W2108134400 cites W2126107475 @default.
• W2108134400 cites W2137282952 @default.
• W2108134400 cites W2158090738 @default.
• W2108134400 cites W2160406420 @default.
• W2108134400 cites W2167704486 @default.
• W2108134400 cites W2170959879 @default.
• W2108134400 cites W2171127338 @default.
• W2108134400 cites W4245157701 @default.
• W2108134400 cites W4255100288 @default.
• W2108134400 doi "https://doi.org/10.1186/1748-717x-8-118" @default.
• W2108134400 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3674983" @default.
• W2108134400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23668632" @default.
• W2108134400 hasPublicationYear "2013" @default.
• W2108134400 type Work @default.
• W2108134400 sameAs 2108134400 @default.
• W2108134400 citedByCount "171" @default.
• W2108134400 countsByYear W21081344002013 @default.
• W2108134400 countsByYear W21081344002014 @default.
• W2108134400 countsByYear W21081344002015 @default.
• W2108134400 countsByYear W21081344002016 @default.
• W2108134400 countsByYear W21081344002017 @default.
• W2108134400 countsByYear W21081344002018 @default.
• W2108134400 countsByYear W21081344002019 @default.
• W2108134400 countsByYear W21081344002020 @default.
• W2108134400 countsByYear W21081344002021 @default.
• W2108134400 countsByYear W21081344002022 @default.
• W2108134400 countsByYear W21081344002023 @default.
• W2108134400 crossrefType "journal-article" @default.
• W2108134400 hasAuthorship W2108134400A5013286247 @default.
• W2108134400 hasAuthorship W2108134400A5030399585 @default.
• W2108134400 hasAuthorship W2108134400A5038451619 @default.
• W2108134400 hasAuthorship W2108134400A5082915859 @default.
• W2108134400 hasBestOaLocation W21081344001 @default.
• W2108134400 hasConcept C121608353 @default.
• W2108134400 hasConcept C126322002 @default.
• W2108134400 hasConcept C126894567 @default.
• W2108134400 hasConcept C159110408 @default.
• W2108134400 hasConcept C2776235491 @default.
• W2108134400 hasConcept C2776651944 @default.
• W2108134400 hasConcept C2778311097 @default.
• W2108134400 hasConcept C2779951463 @default.
• W2108134400 hasConcept C2780192828 @default.
• W2108134400 hasConcept C2780387249 @default.
• W2108134400 hasConcept C2781413609 @default.
• W2108134400 hasConcept C29730261 @default.
• W2108134400 hasConcept C509974204 @default.
• W2108134400 hasConcept C71924100 @default.
• W2108134400 hasConcept C77411442 @default.
• W2108134400 hasConceptScore W2108134400C121608353 @default.
• W2108134400 hasConceptScore W2108134400C126322002 @default.
• W2108134400 hasConceptScore W2108134400C126894567 @default.
• W2108134400 hasConceptScore W2108134400C159110408 @default.
• W2108134400 hasConceptScore W2108134400C2776235491 @default.
• W2108134400 hasConceptScore W2108134400C2776651944 @default.
• W2108134400 hasConceptScore W2108134400C2778311097 @default.
• W2108134400 hasConceptScore W2108134400C2779951463 @default.
• W2108134400 hasConceptScore W2108134400C2780192828 @default.
• W2108134400 hasConceptScore W2108134400C2780387249 @default.
• W2108134400 hasConceptScore W2108134400C2781413609 @default.
• W2108134400 hasConceptScore W2108134400C29730261 @default.
• W2108134400 hasConceptScore W2108134400C509974204 @default.
• W2108134400 hasConceptScore W2108134400C71924100 @default.
• W2108134400 hasConceptScore W2108134400C77411442 @default.
• W2108134400 hasIssue "1" @default.
• W2108134400 hasLocation W21081344001 @default.
• W2108134400 hasLocation W21081344002 @default.
• W2108134400 hasLocation W21081344003 @default.
• W2108134400 hasLocation W21081344004 @default.

• next